Samsung Biologics to manufacture antibodies for Vir’s SARS-CoV-2 mab programme

South Korea’s Samsung Biologics will perform large scale manufacturing services for San Fran company Vir Biotechnology’s SARS-CoV-2 monoclonal antibody (mab) programme under a new manufacturing agreement.

Vir’s lead SARS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays.

Vir plans to proceed directly into a phase 2 clinical trial within the next three to five months. Today’s agreement builds on Vir’s previously announced manufacturing agreement with WuXi Biologics and its letter of intent with Biogen.

Under $362 million deal, Samsung Biologics is expected to commence its manufacturing as early as October with the first engineering run, with potential commercial batches to be manufactured starting in 2021 in Plant 3.

The parties will continue to negotiate additional terms in a definitive agreement and will use best efforts to execute a definitive agreement before July 31, 2020.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news